A number of firms have modified their ratings and price targets on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) recently:

  • 10/9/2017 – Pacira Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt.”
  • 10/4/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at Bank of America Corporation from $46.00 to $45.00. They now have a “buy” rating on the stock.
  • 10/3/2017 – Pacira Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $42.00 price target on the stock. According to Zacks, “Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt.”
  • 10/1/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $44.00 price target on the stock, down previously from $48.00.
  • 9/28/2017 – Pacira Pharmaceuticals is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “neutral” rating and a $41.00 price target on the stock.
  • 9/26/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC.
  • 9/25/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $53.00 price target on the stock.
  • 9/7/2017 – Pacira Pharmaceuticals is now covered by analysts at Oppenheimer Holdings, Inc.. They set a “market perform” rating on the stock.
  • 9/7/2017 – Pacira Pharmaceuticals is now covered by analysts at CIBC. They set a “market perform” rating on the stock.
  • 9/7/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $59.00 price target on the stock.
  • 9/6/2017 – Pacira Pharmaceuticals is now covered by analysts at UBS AG. They set a “market perform” rating on the stock.
  • 9/5/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $54.00 price target on the stock.
  • 8/29/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at Canaccord Genuity from $56.00 to $48.00. They now have a “buy” rating on the stock.
  • 8/23/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
  • 8/22/2017 – Pacira Pharmaceuticals is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $55.00 price target on the stock.
  • 8/22/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $53.00 price target on the stock, down previously from $54.00.
  • 8/21/2017 – Pacira Pharmaceuticals was upgraded by analysts at Janney Montgomery Scott from a “sell” rating to a “neutral” rating. They now have a $31.00 price target on the stock.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) traded down 0.58% during midday trading on Friday, hitting $34.00. The stock had a trading volume of 110,145 shares. The firm’s market cap is $1.37 billion. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.95 and a 52 week high of $58.95. The company’s 50 day moving average is $36.88 and its 200 day moving average is $42.97.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). The business had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.21 earnings per share. On average, equities analysts predict that Pacira Pharmaceuticals, Inc. will post ($0.18) earnings per share for the current fiscal year.

In related news, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the sale, the chief accounting officer now directly owns 21,312 shares in the company, valued at $783,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the sale, the chief executive officer now owns 159,164 shares in the company, valued at $5,788,794.68. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock worth $1,215,480 over the last quarter. 6.60% of the stock is currently owned by corporate insiders.

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.